Debiopharm Overview and Company Profile

Author

Reads 7.8K

Business building
Credit: pexels.com, Business building

Debiopharm is a Swiss-based biopharmaceutical company that has been in operation since 1979. It was founded by Ernest Gut as a small laboratory in Geneva.

Debiopharm's headquarters is located in Lausanne, Switzerland, and it has a presence in several countries worldwide. The company has a strong focus on developing and commercializing innovative therapies.

Debiopharm has a diverse portfolio of products that span multiple therapeutic areas, including oncology, infectious diseases, and rare diseases. The company has a commitment to improving patient outcomes through its research and development efforts.

Organization

Debiopharm is a Life Science division of the holding company Après-demain, which translates to "The Day after Tomorrow".

The company has three subsidiaries focused on different areas: Debiopharm International, Debiopharm Research & Manufacturing, and Debiopharm Innovation Fund. Debiopharm International in-licenses product candidates or technologies, develops them into medicines, and then licenses them to third parties for commercialization.

Debiopharm Research & Manufacturing, based in Martigny, Switzerland, provides contract manufacturing and contract research services to Debiopharm. The Swissmedic-certified production site was renovated and expanded in 2015.

Here are the Debiopharm subsidiaries and their main focuses:

  • Debiopharm International: oncology and infectious diseases
  • Debiopharm Research & Manufacturing: contract manufacturing and contract research services
  • Debiopharm Innovation Fund: investment (formerly managed by Debiopharm Investment SA)

Structure and Subsidiaries

Credit: youtube.com, Organizational Structure

Debiopharm is a Life Science division of the holding company Après-demain, which has a unique structure with three subsidiaries.

Debiopharm International is one of these subsidiaries, focused on developing medicines in oncology and infectious diseases, from preclinical development to full approval.

This subsidiary in-licenses product candidates or technologies, develops them into medicines, and then licenses them to third parties for commercialization.

Debiopharm Research & Manufacturing, formerly known as Debio R.P., is a pharmaceutical research, development, and production company based in Martigny, Switzerland.

Its Swissmedic-certified production site was renovated and expanded in 2015, and it provides contract manufacturing and contract research services to Debiopharm.

Debiopharm is known for developing two drugs that became standards of care for cancer treatment: triptorelin and oxaliplatin.

These drugs are listed on the World Health Organization's List of Essential Medicines.

Here's a brief overview of Debiopharm's subsidiaries:

  • Debiopharm International: develops medicines in oncology and infectious diseases
  • Debiopharm Research & Manufacturing: provides contract manufacturing and contract research services

Headquarters Location

Our organization's headquarters is located in Lausanne, Switzerland.

You can find us at Chemin Messidor 5-7, Case postale 5911.

The postal code for our location is 1002.

If you need to get in touch with us, you can call +41 (0) 21 321 0111.

Employment Numbers

Empty corridor with doors in office center
Credit: pexels.com, Empty corridor with doors in office center

411 people are employed at Debiopharm.

Debiopharm has a significant workforce, which is a testament to its growth and success.

SIC Code Lookup

If you're looking to get a business off the ground, understanding SIC codes is crucial.

Debiopharm's SIC codes are 283, 80, 28, and 807.

SIC codes help organizations like Debiopharm get classified and identified within the industry.

The SIC codes for Debiopharm are specifically for pharmaceutical and chemical manufacturing, as well as other related industries.

Financials

Debiopharm's annual revenue was $141.8 million in 2025.

The company's financial performance is a key indicator of its growth and success.

Debiopharm's annual revenue was $141.8 million in 2025.

Leadership and Management

At the helm of Debiopharm is Bertrand Ducrey, the CEO who has been instrumental in driving the company's success.

Bertrand Ducrey's leadership has been crucial in shaping Debiopharm's direction and vision.

With a strong and experienced leadership team, Debiopharm is well-equipped to tackle the challenges of the pharmaceutical industry.

Investments and Acquisitions

Credit: youtube.com, Debiopharm Innovation Fund

Debiopharm Group has made a total of 17 investments, with their latest being in Neuroute as part of their Seed investment on September 28, 2023.

Their investments have spanned various stages, including Series A, and have involved companies in the healthcare and biotechnology sectors.

Debiopharm Group has acquired 4 companies, with their latest acquisition being ImmunoGen - Antibody-Drug Conjugate on May 24, 2017.

Here's a breakdown of their acquisitions:

Under Development

Debiopharm is actively working on several early-stage treatments, including a treatment targeting the CAIX enzyme to fight cancer progression, which was out-licensed to ITM in 2024.

This treatment, referred to as "Debio 0228", is a result of Debiopharm's partnership with German biotech 3B Pharmaceuticals (3BP). Debiopharm has also partnered with Merck KGaA for the development and commercialization of xevinapant.

Xevinapant is an orally available inhibitor of apoptosis proteins that has shown efficiency in high-risk patients with locally advanced squamous-cell carcinoma of the head and neck. Unfortunately, Merck dropped the project in 2024, after acquiring the license for 900 million euros in 2021.

Consider reading: Merck Group

Credit: youtube.com, Six Acquisitions in Three Years with Ryan Sullivan

Debiopharm's pipeline also includes several other promising treatments, such as afabicin, an antistaphylococcal antibiotic for acute bacterial skin and skin structure infections, and Debio 0123, a WEE1 inhibitor for the treatment of glioblastoma.

Here's a list of some of the treatments currently under development by Debiopharm:

  • Debio 0228: a treatment targeting the CAIX enzyme to fight cancer progression
  • Afabicin: an antistaphylococcal antibiotic for acute bacterial skin and skin structure infections
  • Debio 0123: a WEE1 inhibitor for the treatment of glioblastoma
  • Debio 1562M: a second-generation ADC directed against CD37 and including Multilink cleavable linker-payload technology
  • Debio 4126: a sustained-release formulation of somatostatin analogue (SSA) therapy for the treatment of acromegaly
  • Debio 4326: a gonadotropin-releasing hormone agonist therapy for central precocious puberty

Investments

Debiopharm Group has made a significant number of investments, with a total of 17 investments under their belt.

Their latest investment was in Neuroute, a company they invested in as part of their Seed round on September 28, 2023.

These investments demonstrate Debiopharm Group's commitment to supporting innovative companies and ideas.

A fresh viewpoint: AsiaPak Investments

Acquisitions

Debiopharm Group has made some significant acquisitions over the years. Their latest acquisition was ImmunoGen - Antibody-Drug Conjugate on May 24, 2017.

This acquisition was worth $XXM. Debiopharm Group has also made acquisitions in the past, but the details of those deals are not publicly available due to subscription requirements.

Interestingly, Debiopharm Group's acquisitions have been spread across different investment stages. One notable example is the Series A investments in 2016, with two separate deals worth $XXM each.

Here are the details of Debiopharm Group's acquisitions:

Portfolio Exits

Credit: youtube.com, Understanding Private Equity Exit Strategies

Debiopharm Group has a total of 2 portfolio exits, which is a significant indicator of their investment strategy and success.

Their latest portfolio exit was ABAC Therapeutics, which was acquired by Tibidabo Ventures on November 21, 2019, for a valuation of $XXM.

The company's first portfolio exit was an IPO, which took place on April 27, 2015, but the exact valuation and acquirer are not publicly disclosed due to subscription requirements.

Debiopharm Group has had two notable portfolio exits, one being an acquisition and the other an IPO.

Here's a summary of their portfolio exits:

Partners & Customers

Debiopharm has partnered with several companies to advance its research and development goals.

Debiopharm has 10 strategic partners and customers.

One of Debiopharm's recent partnerships is with Ubiquigent, a UK-based company that specializes in drug discovery and development. Ubiquigent and Debiopharm entered into an agreement on March 26, 2024, to support the USP1 inhibitor program for Debio 0432.

White 15120 Building
Credit: pexels.com, White 15120 Building

Debiopharm has also partnered with TransCode Therapeutics, a US-based company that focuses on targeted nucleic acid therapeutics for cancer. Their collaboration aims to develop innovative cancer treatments.

In addition to these partnerships, Debiopharm has partnered with Genialis, a US-based RNA-biomarker company. Together, they are working to define and discover biomarkers within the DNA Damage Repair biology space.

Debiopharm's partnerships with ThinkingNodeLife.ai and Repare Therapeutics were also announced in January 2024. However, the details of these collaborations are not publicly available.

Here are the details of Debiopharm's partnerships:

Fund History and Performance

Debiopharm Group has a fund history that's worth exploring.

Debiopharm Group has one fund, the Debiopharm Innovation Fund, as of the available data.

The Debiopharm Innovation Fund has a status that is not specified in the available data.

The amount of the Debiopharm Innovation Fund is also not specified in the available data.

Additional reading: Cottonwood Technology Fund

Frequently Asked Questions

What is the history of Debiopharm?

Debiopharm was founded in 1979 by Rolland-Yves Mauvernay in Martigny, Switzerland. The company has since evolved through various name changes, including Debio Recherche Pharmaceutique and Debiopharm Research & Manufacturing.

Micheal Pagac

Senior Writer

Michael Pagac is a seasoned writer with a passion for storytelling and a keen eye for detail. With a background in research and journalism, he brings a unique perspective to his writing, tackling a wide range of topics with ease. Pagac's writing has been featured in various publications, covering topics such as travel and entertainment.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.